Table 4.
Univariate analysis for 5-year bDFS of two different groups: patients treated with and without hormonal therapy (HT).
| Patients treated with HT 148 pts (52%) |
Patients treated without HT 134 pts (48%) |
|||
|---|---|---|---|---|
| 5-year bDFS % (95% CI) | p value* | 5-year bDFS % (95% CI) | p value* | |
| PSA cut-off | ||||
| <0.2 ng/ml ART | 64% (95% CI 17–89) | 0.22 | 89% (95% CI 78–94) | 0.19 |
| ≥0.2 ng/ml SRT | 66% (95% CI 55–76) | 74% (95% CI 58–85) | ||
| <0.02 ng/ml ART | 64% (95% CI 17–89) | 0.21 | 97% (95% CI 80–99) | 0.13 |
| ≥0.02 ng/ml SRT | 66% (95% CI 55–76) | 76% (95% CI 65–84) | ||
| Risk class17 | ||||
| Low risk | 84% (95% CI 65–93) | 0.20 | 88% (95% CI 75–95) | 0.12 |
| Intermediate risk | 67% (95% CI 45–81) | 69% (95% CI 46–84) | ||
| High risk | 55% (95% CI 34–71) | 76% (95% CI 50–89) | ||
| Pathological N status | ||||
| pN0 | 65% (95% CI 50–76) | 0.0022 | 80% (95% CI 67–88) | 0.28 |
| pN1 | 35% (95% CI 9–62) | – | ||
| pNx | 91% (95% CI 73–97) | 87% (95% CI 74–94) | ||
| Pathological Gleason score | ||||
| 3–6 (61 pts, 22%) | 93% (95% CI 59–99) | 0.002 | 93% (95% CI 75–98) | 0.13 |
| 7 (125 pts, 44%) | 78% (95% CI 61–89) | 81% (95% CI 68–89) | ||
| 8–10 (96 pts, 34%) | 45% (95% CI 27–62) | 77% (95% CI 56–89) | ||
| Surgical margins | ||||
| Positive | 82% (95% CI 62–91) | 0.22 | 83% (95% CI 70–96) | 0.15 |
| Negative | 60% (95% CI 45–72) | 82% (95% CI 72–89) | ||
*
Log-rank test.